KURA Kura Oncology Inc.

34.09
-0.56  -2%
Previous Close 34.65
Open 34.35
52 Week Low 6.35
52 Week High 43
Market Cap $2,251,119,139
Shares 66,034,589
Float 56,881,606
Enterprise Value $1,941,132,139
Volume 705,648
Av. Daily Volume 940,200
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
KO-539
Relapsed or refractory acute myeloid leukemia (AML)
Phase 1
Phase 1
Phase 1/2 trial presentation at ASH December 5, 2020. 6/8 patients showed clinical activity.
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2
Phase 2
Registration-directed trial to be initiated.
Tipifarnib
Head and neck squamous cell carcinomas (HNSCC) with HRAS Mutations
Phase 2
Phase 2
Phase 2 mature data presented at ASCO May 29, 2020 - Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC
KO-947
Solid tumors
Phase 1
Phase 1
Phase 1 development terminated - May 4, 2020.
Tipifarnib - (AIM-HN/SEQ-HN)
Head and neck squamous cell carcinomas (HNSCC)
Phase 2
Phase 2
Phase 2 enrolling.

Latest News

  1. SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the H.C. Wainwright BioConnect 2021 Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel discussion on precision medicine on Wednesday, January 13, 2021 at 9:00 a.m. PT / 12:00 p.m. ET. The panel, entitled "The Importance of Biomarkers and Cytogenetic Profiling in Drug Discovery, Development and Commercialization," will be led by Scott Gottlieb, M.D., 23rd Commissioner of the U.S. Food and Drug Administration.

    A live audio webcast of…

    SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the H.C. Wainwright BioConnect 2021 Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel discussion on precision medicine on Wednesday, January 13, 2021 at 9:00 a.m. PT / 12:00 p.m. ET. The panel, entitled "The Importance of Biomarkers and Cytogenetic Profiling in Drug Discovery, Development and Commercialization," will be led by Scott Gottlieb, M.D., 23rd Commissioner of the U.S. Food and Drug Administration.

    A live audio webcast of the panel discussion will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura's most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company's pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company's website at www.kuraoncology.com.

    Contacts

    Company:

    Pete De Spain

    Vice President, Investor Relations &

    Corporate Communications

    (858) 500-8803

    Investors:

    Robert H. Uhl

    Managing Director

    Westwicke ICR

    (858) 356-5932

    Media:

    Jason Spark

    Managing Director

    Canale Communications

    (619) 849-6005



    Primary Logo

    View Full Article Hide Full Article
  2. SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 39th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, January 12, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The virtual conference will be held from January 11-14, 2021.

    A live audio webcast of the presentation will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

    About Kura Oncology

    SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 39th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, January 12, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The virtual conference will be held from January 11-14, 2021.

    A live audio webcast of the presentation will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura's most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company's pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company's website at www.kuraoncology.com.

    Contacts

    Company:

    Pete De Spain

    Vice President, Investor Relations &

    Corporate Communications

    (858) 500-8803

    Investors:

    Robert H. Uhl

    Managing Director

    Westwicke ICR

    (858) 356-5932

    Media:

    Jason Spark

    Managing Director

    Canale Communications

    (619) 849-6005

     



    Primary Logo

    View Full Article Hide Full Article
  3. SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 9,326,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,216,500 shares, at a public offering price of $37.00 per share. The gross proceeds to Kura from the offering, before underwriting discounts and commissions and other offering expenses payable by Kura, were approximately $345.1 million.

    SVB Leerink, Credit Suisse, Barclays and Stifel acted as joint bookrunning managers…

    SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 9,326,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,216,500 shares, at a public offering price of $37.00 per share. The gross proceeds to Kura from the offering, before underwriting discounts and commissions and other offering expenses payable by Kura, were approximately $345.1 million.

    SVB Leerink, Credit Suisse, Barclays and Stifel acted as joint bookrunning managers in the offering. Wedbush PacGrow, JMP Securities and H.C. Wainwright & Co. acted as co-managers in the offering.

    The securities described above were offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura and became effective by rule of the Securities and Exchange Commission (the "SEC") on December 7, 2020. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at ; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at ; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at or by telephone at (888) 603-5847; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by email at  or by telephone at (415) 364-2720.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura's most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company's pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed or refractory acute myeloid leukemia.

    Contacts

    Company:

    Pete De Spain

    Vice President, Investor Relations &

    Corporate Communications

    (858) 500-8803

    Investors:

    Robert H. Uhl

    Managing Director

    Westwicke ICR

    (858) 356-5932

    Media:

    Jason Spark

    Managing Director

    Canale Communications

    (619) 849-6005



    Primary Logo

    View Full Article Hide Full Article
  4. SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat on Tuesday, December 15, 2020 at 11:00 a.m. ET / 8:00 a.m. PT. The virtual forum will be held from December 15-16, 2020.

    A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

    About Kura Oncology

    Kura Oncology…

    SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat on Tuesday, December 15, 2020 at 11:00 a.m. ET / 8:00 a.m. PT. The virtual forum will be held from December 15-16, 2020.

    A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura's most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company's pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company's website at www.kuraoncology.com.

    Contacts

    Company:

    Pete De Spain

    Vice President, Investor Relations &

    Corporate Communications

    (858) 500-8803

    Investors:

    Robert H. Uhl

    Managing Director

    Westwicke ICR

    (858) 356-5932

    Media:

    Jason Spark

    Managing Director

    Canale Communications

    (619) 849-6005



    Primary Logo

    View Full Article Hide Full Article
  5. SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public of $37.00 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $300 million. In addition, Kura has granted the underwriters a 30-day option to purchase up to an additional 1,216,500 shares of common stock. The offering is expected to close on or about December 11, 2020, subject…

    SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public of $37.00 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $300 million. In addition, Kura has granted the underwriters a 30-day option to purchase up to an additional 1,216,500 shares of common stock. The offering is expected to close on or about December 11, 2020, subject to customary closing conditions.

    SVB Leerink, Credit Suisse, Barclays and Stifel are acting as joint bookrunning managers in the offering. Wedbush PacGrow, JMP Securities and H.C. Wainwright & Co. are acting as co-managers for the offering.

    The securities described above are being offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura and became effective by rule of the Securities and Exchange Commission (the "SEC") on December 7, 2020. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at ; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at ; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at or by telephone at (888) 603-5847; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by email at  or by telephone at (415) 364-2720.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura's most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company's pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed or refractory acute myeloid leukemia.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements regarding the completion, timing and size of the offering. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Kura's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with market conditions and the satisfaction of closing conditions related to the offering, risks and uncertainties associated with Kura's business and finances in general, risks associated with the COVID-19 global pandemic, and the other risks described in Kura's quarterly report on Form 10-Q for the quarterly period ended September 30, 2020, the preliminary prospectus supplement relating to the proposed public offering and other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Kura undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Contacts

    Company:

    Pete De Spain

    Vice President, Investor Relations &

    Corporate Communications

    (858) 500-8803

    Investors:

    Robert H. Uhl

    Managing Director

    Westwicke Partners, LLC

    (858) 356-5932

    Media:

    Jason Spark

    Managing Director

    Canale Communications

    (619) 849-6005



    Primary Logo

    View Full Article Hide Full Article
View All Kura Oncology Inc. News